🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesMetabolic syndrome reversal — May 2025 Page 2

Metabolic syndrome reversal — May 2025

james_edin Mon, Oct 27, 2025 at 11:27 PM 6 replies 1,096 viewsPage 2 of 2
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Oct 28, 2025 at 1:11 AM#6
Dr.PeteFamMed said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

My labs after 6 months on glycaemic control: A1C 5.7%, fasting glucose 92 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.9% and fasting glucose was 117 mg/dL. The improvement has been dramatic and consistent.

44 14FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 41 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Oct 28, 2025 at 1:51 AM#7
james_edin said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Oct 28, 2025 at 2:51 AM
43 13mike_nyc, VendorMark, COA_Karl and 40 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Oct 28, 2025 at 2:31 AM#8
CarlaRPh_TPA said:
My labs after 6 months on glycaemic control: A1C 5.7%, fasting glucose 92 mg/dL, fasting insulin 5 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)124988882
Insulin (fasting)201285
HOMA-IR4.54.01.61.3
Uric Acid8.76.45.55.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

42 12paul_denver, TinaHashiRN, robert_kc and 39 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Oct 28, 2025 at 3:11 AM#9

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

41 11JessicaM_2024, TomFromTexas, mike.trainer_LA and 38 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Oct 28, 2025 at 6:25 AM#10
EndoResFellow said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.3 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

33 6bbq_ray_KC, oliver_london, tane_welly and 30 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register